Somatropin (rDNA origin) ( DrugBank: Somatropin )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
78	Hypopituitarism	3

78. Hypopituitarism

---

Clinical trials : 494 /  Drugs : 385 - (DrugBank : 49) / Drug target genes : 44 - Drug target pathways : 100

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02311894 (ClinicalTrials.gov)	March 31, 2015	4/12/2014	A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency	A Phase IV, Multicenter, Open-Label Study of the Immunogenicity of Nutropin AQ® V1.1 [Somatropin (rDNA Origin) Injection] Administered Daily to Naïve Growth Hormone-Deficient Children (iSTUDY)	Growth Hormone Deficiency	Drug: Somatropin	Genentech, Inc.	NULL	Completed	3 Years	14 Years	All	82	Phase 4	United States
2	NCT00600808 (ClinicalTrials.gov)	June 2003	23/7/2007	Sustained Release Formulation of Somatropin (rDNA Origin)for Injection	A Phase II/IIIa, Assessor Blinded (Partially Blinded), Randomised, Active-Controlled, Multicentre, Parallel-Group Study of the Safety, Efficacy and pk/pd of LB03002 Administered Weekly in Children With Growth Failure Due to GH Deficiency.	Growth Hormone Deficiency	Drug: BPLG-003	BioPartners GmbH	LG Life Sciences	Completed	4 Years	10 Years	Both	51	Phase 2/Phase 3	NULL
3	NCT01088399 (ClinicalTrials.gov)	September 2002	25/2/2010	A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults	The Global Hypopituitary Control and Complications Study	Hypopituitarism;Pituitary Insufficiency;Growth Hormone Deficiency, Adult	Drug: Somatropin (rDNA origin)	Eli Lilly and Company	NULL	Completed	18 Years	N/A	All	10673	N/A	NULL